These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2598972)

  • 41. N-acetylation phenotyping with sulfamethazine in an Iranian population.
    Sardaş S; Lahijany B; Cok I; Karakaya AE
    Pharmacogenetics; 1993 Jun; 3(3):131-4. PubMed ID: 8334437
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug acetylation and expression of lupus erythematosus.
    Marsden JR; Mason GG; Coburn PR; Rawlins MD; Shuster S
    Eur J Clin Pharmacol; 1985; 28(4):387-90. PubMed ID: 4029245
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymorphic acetylation of sulphamethazine in a Zimbabwe population.
    Nhachi CF
    J Med Genet; 1988 Jan; 25(1):29-31. PubMed ID: 3351888
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polymorphic acetylation of the antibacterials, sulfamethazine and dapsone, in South Indian subjects.
    Peters JH; Gordon GR; Karat AB
    Am J Trop Med Hyg; 1975 Jul; 24(4):641-8. PubMed ID: 1155699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acetylator phenotype among individuals with glucose 6-phosphate dehydrogenase variants.
    Jeyakumar LH; French MR
    Xenobiotica; 1986 Dec; 16(12):1129-32. PubMed ID: 3798960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymorphically acetylated aminoglutethimide in humans.
    Coombes RC; Foster AB; Harland SJ; Jarman M; Nice EC
    Br J Cancer; 1982 Sep; 46(3):340-5. PubMed ID: 7126424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
    Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
    Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polymorphic N-acetylation of sulfamethazine and benzidine by human liver: implication for cancer risk?
    Peters JH; Gordon GR; Lin E; Green CE; Tyson CA
    Anticancer Res; 1990; 10(1):225-9. PubMed ID: 2334132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The S-acetyl coenzyme A-dependent metabolic activation of the carcinogen N-hydroxy-2-aminofluorene by human liver cytosol and its relationship to the aromatic amine N-acetyltransferase phenotype.
    Flammang TJ; Yamazoe Y; Guengerich FP; Kadlubar FF
    Carcinogenesis; 1987 Dec; 8(12):1967-70. PubMed ID: 3677322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determination of the acetylator phenotype in a Northern Nigerian population.
    Fawcett IW; Gammon PT
    Tubercle; 1975 Sep; 56(3):199-201. PubMed ID: 1216338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between acetylator phenotype and intensity of the hypoglycaemic effect of a suplhonamide preparation in children with insulin-dependent diabetes.
    Hadasová E; Brysová V; Utĕsený J; Macků M
    Bratisl Lek Listy; 1991 Dec; 92(12):609-14. PubMed ID: 1806177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acetylator phenotype in spontaneous SLE and rheumatoid arthritis.
    Lawson DH; Henry DA; Lowe J; Reavey P; Rennie JA; Solomon A
    Ann Rheum Dis; 1979 Apr; 38(2):171-3. PubMed ID: 443884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The relationship between the acetylator and the sparteine hydroxylation polymorphisms.
    Harmer D; Evans DA; Eze LC; Jolly M; Whibley EJ
    J Med Genet; 1986 Apr; 23(2):155-6. PubMed ID: 3712391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics, metabolism, and renal excretion of sulfadimidine and its N4-acetyl and hydroxy metabolites in humans.
    Vree TB; Hekster YA; Nouws JF; Baakman M
    Ther Drug Monit; 1986; 8(4):434-9. PubMed ID: 3824429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of double genetic polymorphism on response to sulfamethazine.
    Woolhouse NM; Atu-Taylor LC
    Clin Pharmacol Ther; 1982 Mar; 31(3):377-83. PubMed ID: 7060320
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acetylation phenotype in hypertensive patients.
    Huang CY; Chu JY; Yen TC
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Jan; 8(1):1-5. PubMed ID: 1548734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acetylation phenotype and skin complexion.
    Rampen FH; van der Meeren HL; Stolk LM
    Acta Derm Venereol; 1986; 66(4):334-6. PubMed ID: 2430405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation.
    Oyama T; Kawamoto T; Mizoue T; Yasumoto K; Kodama Y; Mitsudomi T
    Anticancer Res; 1997; 17(1B):577-81. PubMed ID: 9066583
    [TBL] [Abstract][Full Text] [Related]  

  • 59. N-acetylation of drugs: search for INH acetylation polymorphism in baboons.
    Radtke HE; Brenner W; Weber WW
    Drug Metab Dispos; 1979; 7(3):194-5. PubMed ID: 38093
    [No Abstract]   [Full Text] [Related]  

  • 60. No effect of smoking on sulfamethazine acetylation.
    Miller ME; Cosgriff JM
    Drug Intell Clin Pharm; 1984; 18(7-8):620-2. PubMed ID: 6745090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.